In 2017, CADTH began preliminary work on a Therapeutic Review to assess new third-line drug therapies for type 2 diabetes and provide recommendations on their optimal use. The drugs included in this review included dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 analogues, and sodium-glucose cotransporter-2 inhibitors.
In January 2018...
CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.
Orkambi
Brand name
Generic name
Manufacturer
I...
A draft report on Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism is now available for feedback from all interested stakeholders.
Project
Call for Feedback
Feedback Due By
Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism
2018-01-22
2018-02-06
Consultation Document
Product Type
Submit Stakeholder Feedback
Draft Re...
June 1, 2018 - June 5, 2018
CADTH is pleased to be co-hosting the Health Technology Assessment international (HTAi) 2018 Annual Meeting in Vancouver, British Columbia, June 1 to 5, 2018. Dr. Tammy Clifford, Chief Scientist and Vice-President of Evidence Standards and Medical Devices at CADTH, is a co-chair of the International Scientific Programme Committee.
The theme of t...
